Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 12/20 | 0.61 |
| ▸ | HRH1 | P35367 | 12/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.44 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6398613 | 0.83 | CCR3 (0.63) | CCR3HRH1KCNH2HRH3UTS2R | |
| SCHEMBL5657070 | 0.81 | CCR3 (0.67) | CCR3HRH1KCNH2 | |
| SCHEMBL6403935 | 0.81 | CCR3 (0.73) | CCR3HRH1KCNH2HRH3UTS2R | |
| SCHEMBL6397002 | 0.80 | CCR3 (0.78) | CCR3HRH1KCNH2HRH3UTS2R | |
| SCHEMBL6403955 | 0.80 | CCR3 (0.64) | CCR3HRH1KCNH2HRH3UTS2R | |
| SCHEMBL6396607 | 0.80 | CCR3 (0.68) | CCR3HRH1KCNH2 | |
| SCHEMBL6397190 | 0.80 | CCR3 (0.63) | CCR3HRH1KCNH2HRH3UTS2R | |
| SCHEMBL6398901 | 0.79 | CCR3 (0.68) | CCR3HRH1KCNH2 | |
| SCHEMBL6397907 | 0.79 | CCR3 (0.82) | CCR3HRH1KCNH2HRH3UTS2R | |
| SCHEMBL6395799 | 0.79 | CCR3 (0.72) | CCR3HRH1KCNH2HRH3UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030134840-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2003-07-17 | — | — | US | claimed |
| JP-2002540204-A | — | — | 2002-11-26 | — | — | JP | claimed |
| EP-1165545-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-01-02 | — | — | EP | claimed |
| WO-2000058305-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-10-05 | — | — | WO | claimed |
| US-6946478-B2 | Compounds | ASTRAZENECA AB (SE) | 2005-09-20 | — | — | US | disclosed |
| US-20030134840-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2003-07-17 | — | — | US | disclosed |
| US-6518286-B1 | Piperidinyl compounds for modulation of immune and inflammatory responses in various diseases and disorders, including asthma | ASTRAZENECA AB (SE) | 2003-02-11 | — | — | US | disclosed |
| EP-1165545-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058305-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134840-A1 | Novel compounds | RPS4X, RPS4Y1, CYP4B1 | CCR3 894/4885HRH1 802/4885KCNH2 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.